Canakinumab fails to meet primary endpoint in non-small cell lung cancer phase III trial

In the CANOPY-2 trial (n=237), canakinumab failed to improve overall survival in adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) after progression following platinum chemotherapy and checkpoint inhibitor immunotherapy.

Source:

Biospace Inc.